Eli Lilly Dealt Another Setback as Lung Cancer Drug Flunks Phase III Test Post author:Sam Post published:October 9, 2017 Post category:BioPharma October 10, 2017By Alex Keown, BioSpace.com Breaking… Source: BioSpace You Might Also Like Actelion Provides An Update On The Progress Towards Launching – Key Results For Pipeline Assets To Be Developed By May 21, 2017 AstraZeneca Canada Release: Pan-Canadian Oncology Drug Review Recommendation Supports The Use Of Tagrisso (Osimertinib) As The Standard Of Care For T790M Mutated Non-Small Cell Lung Cancer May 7, 2017 Celgene Cuddles Up With Another Cambridge Biotech, This Time to Tackle Autoimmune Diseases October 2, 2017
Actelion Provides An Update On The Progress Towards Launching – Key Results For Pipeline Assets To Be Developed By May 21, 2017
AstraZeneca Canada Release: Pan-Canadian Oncology Drug Review Recommendation Supports The Use Of Tagrisso (Osimertinib) As The Standard Of Care For T790M Mutated Non-Small Cell Lung Cancer May 7, 2017
Celgene Cuddles Up With Another Cambridge Biotech, This Time to Tackle Autoimmune Diseases October 2, 2017
